Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15511682,trough,"Blood samples determined trough and peak plasma levels; levels were 27.0 +/- 9.4 microg/ml and 33.8 +/- 10.8 microg/ml, respectively, with ratios as small as 1.28 +/- 0.15.",Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],27.0,444,DB00909,Zonisamide
,15511682,peak plasma levels,"Blood samples determined trough and peak plasma levels; levels were 27.0 +/- 9.4 microg/ml and 33.8 +/- 10.8 microg/ml, respectively, with ratios as small as 1.28 +/- 0.15.",Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],33.8,445,DB00909,Zonisamide
,15511682,trough plasma levels,Seizures were not controlled in 23 of 72 patients; low trough plasma levels (approximately 15 microg/ml) were observed.,Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],15,446,DB00909,Zonisamide
>,15511682,peak plasma levels,Drowsiness/short attention span in five patients instigated a dosage decrease (peak plasma levels >40 microg/ml).,Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511682/),[μg] / [ml],40,447,DB00909,Zonisamide
,34004072,peak plasma zonisamide (Cmax ),"For Phase 1, peak plasma zonisamide (Cmax ) was 15 ± 3 µg/ml at 2 ± 1 hr (Tmax ).",Pharmacokinetics of zonisamide after oral single dosing and multiple-dose escalation administration in domestic chickens (Gallus gallus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34004072/),[μg] / [ml],15,939,DB00909,Zonisamide
,34004072,Tmax,"For Phase 1, peak plasma zonisamide (Cmax ) was 15 ± 3 µg/ml at 2 ± 1 hr (Tmax ).",Pharmacokinetics of zonisamide after oral single dosing and multiple-dose escalation administration in domestic chickens (Gallus gallus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34004072/),h,2,940,DB00909,Zonisamide
,34004072,disappearance half-life,The disappearance half-life was 6.5 ± 1 hr.,Pharmacokinetics of zonisamide after oral single dosing and multiple-dose escalation administration in domestic chickens (Gallus gallus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34004072/),h,6.5,941,DB00909,Zonisamide
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00909,Zonisamide
,23626393,total run time of analysis,"The total run time of analysis was 3.5 min and the lower limits of detection and quantification were 0.005 and 0.015 μg/ml, respectively.",Rapid and sensitive high performance liquid chromatographic determination of zonisamide in human serum application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23626393/),min,3.5,30408,DB00909,Zonisamide
,24874192,recoveries,"Analytical recoveries of ZNM and IS from spiked human and rabbit plasma samples were in the range of 70.8-77.3% and 85.6-110.4%, respectively.",A simple and accurate liquid chromatography-tandem mass spectrometry method for quantification of zonisamide in plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874192/),%,70.8-77.3,48715,DB00909,Zonisamide
,24874192,recoveries,"Analytical recoveries of ZNM and IS from spiked human and rabbit plasma samples were in the range of 70.8-77.3% and 85.6-110.4%, respectively.",A simple and accurate liquid chromatography-tandem mass spectrometry method for quantification of zonisamide in plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874192/),%,85.6-110.4,48716,DB00909,Zonisamide
,8924916,volume of distribution (V),"The volume of distribution (V) was estimated to be 1.231/kg in a typical 42-kg patient, assuming that the bioavailability of orally administered phenytoin is 100%.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),1/[kg],1.231,57232,DB00909,Zonisamide
,8924916,bioavailability,"The volume of distribution (V) was estimated to be 1.231/kg in a typical 42-kg patient, assuming that the bioavailability of orally administered phenytoin is 100%.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),%,100,57233,DB00909,Zonisamide
,8924916,maximal elimination rate (V(max)),"The maximal elimination rate (V(max)) and the Michaelis-Menten constant (K(m)) were 9.80 mg/d/kg and 9.19 micrograms/ml, respectively.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),[mg] / [d·kg],9.80,57234,DB00909,Zonisamide
,8924916,Michaelis-Menten constant (K(m)),"The maximal elimination rate (V(max)) and the Michaelis-Menten constant (K(m)) were 9.80 mg/d/kg and 9.19 micrograms/ml, respectively.",Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924916/),[μg] / [ml],9.19,57235,DB00909,Zonisamide
,7987503,detection limit,The detection limit was 0.1 micrograms/ml in serum.,Simple and sensitive assay of zonisamide in human serum by high-performance liquid chromatography using a solid-phase extraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987503/),[μg] / [ml],0.1,61272,DB00909,Zonisamide
,26751267,total C/D ratio,"The interindividual pharmacokinetic variability was extensive, as illustrated by a 100-fold variability in serum concentration compared with dose (total C/D ratio 0.03-3.29 µmol·L·mg).",Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751267/),l·mg·μM,0.03-3.29,70769,DB00909,Zonisamide
,19000278,plasma C(max),"After single PO dosing, plasma C(max) was 14.4 +/- 2.3 mcg/mL and elimination half-life was 17.2 +/- 3.6 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),[mcg] / [ml],14.4,76444,DB00909,Zonisamide
,19000278,elimination half-life,"After single PO dosing, plasma C(max) was 14.4 +/- 2.3 mcg/mL and elimination half-life was 17.2 +/- 3.6 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),h,17.2,76445,DB00909,Zonisamide
,19000278,volume of distribution,"After IV dosing, volume of distribution was 1.1 +/- 0.25 L/kg, clearance was 58 +/- 11 mL/h/kg and elimination t(1/2) was 12.9 +/- 3.6 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),[l] / [kg],1.1,76446,DB00909,Zonisamide
,19000278,clearance,"After IV dosing, volume of distribution was 1.1 +/- 0.25 L/kg, clearance was 58 +/- 11 mL/h/kg and elimination t(1/2) was 12.9 +/- 3.6 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),[ml] / [h·kg],58,76447,DB00909,Zonisamide
,19000278,elimination t(1/2),"After IV dosing, volume of distribution was 1.1 +/- 0.25 L/kg, clearance was 58 +/- 11 mL/h/kg and elimination t(1/2) was 12.9 +/- 3.6 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),h,12.9,76448,DB00909,Zonisamide
,19000278,Oral bioavailability,Oral bioavailability was 68 +/- 12%; fraction of unbound drug approximated 60%.,Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),%,68,76449,DB00909,Zonisamide
,19000278,fraction of unbound drug,Oral bioavailability was 68 +/- 12%; fraction of unbound drug approximated 60%.,Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),%,60,76450,DB00909,Zonisamide
,19000278,Plasma C(max) at steady-state,"At steady-state (4 days), differences occurred for for all parameters except C(max) and C(min.) Plasma C(max) at steady-state was 56 +/- 12 mcg/mL, with 10% fluctuation between C(max) and C(min.) Plasma t(1/2) (h) was 23.52 +/- 5.76 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),[mcg] / [ml],56,76451,DB00909,Zonisamide
,19000278,Plasma t(1/2),"At steady-state (4 days), differences occurred for for all parameters except C(max) and C(min.) Plasma C(max) at steady-state was 56 +/- 12 mcg/mL, with 10% fluctuation between C(max) and C(min.) Plasma t(1/2) (h) was 23.52 +/- 5.76 h.",Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000278/),h,23.52,76452,DB00909,Zonisamide
,20205992,elimination half-life,"Its elimination half-life is very long, around 60 h.",[Therapeutic drug monitoring of zonisamide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20205992/),h,60,86087,DB00909,Zonisamide
,8205132,volume of distribution (V),"The volume of distribution (V) was estimated to be 1.27 l/kg in a typical 33-kg patient, assuming that the bioavailability of orally administered zonisamide is 100%.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[l] / [kg],1.27,86252,DB00909,Zonisamide
,8205132,bioavailability,"The volume of distribution (V) was estimated to be 1.27 l/kg in a typical 33-kg patient, assuming that the bioavailability of orally administered zonisamide is 100%.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),%,100,86253,DB00909,Zonisamide
,8205132,maximal daily dose to be cleared (Vmax),"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[mg] / [d·kg],27.6,86254,DB00909,Zonisamide
,8205132,concentration giving,"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[mg] / [d·kg],27.6,86255,DB00909,Zonisamide
,8205132,half maximal clearance (a Michaelis-Menten constant),"The maximal daily dose to be cleared (Vmax) and the concentration giving half maximal clearance (a Michaelis-Menten constant) was 27.6 mg/d/kg and 45.9 micrograms/ml, respectively.",Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205132/),[μg] / [ml],45.9,86256,DB00909,Zonisamide
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00909,Zonisamide
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00909,Zonisamide
,25818215,maximum plasma zonisamide concentrations,Mean maximum plasma zonisamide concentrations (μg/mL) were significantly higher after oral administration (11.56 ± 4.04) compared to H2O-R (5.00 ± 1.83) (P = .004).,Pharmacokinetics of single-dose rectal zonisamide administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818215/),[μg] / [ml],11.56,118955,DB00909,Zonisamide
,25818215,maximum plasma zonisamide concentrations,Mean maximum plasma zonisamide concentrations (μg/mL) were significantly higher after oral administration (11.56 ± 4.04) compared to H2O-R (5.00 ± 1.83) (P = .004).,Pharmacokinetics of single-dose rectal zonisamide administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818215/),[μg] / [ml],5.00,118956,DB00909,Zonisamide
,25818215,relative bioavailability,Mean relative bioavailability of PEG-R (85 ± 69%) was significantly higher than that of H2O-R (53 ± 37%) (P = .039).,Pharmacokinetics of single-dose rectal zonisamide administration in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818215/),%,85,118957,DB00909,Zonisamide
,25818215,relative bioavailability,Mean relative bioavailability of PEG-R (85 ± 69%) was significantly higher than that of H2O-R (53 ± 37%) (P = .039).,Pharmacokinetics of single-dose rectal zonisamide administration in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818215/),%,53,118958,DB00909,Zonisamide
,25818215,minimum therapeutic concentrations,"A dose higher than what was used in this study might be necessary, if currently recommended minimum therapeutic concentrations (10 μg/mL) are to be achieved with a single-dose administration.",Pharmacokinetics of single-dose rectal zonisamide administration in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818215/),[μg] / [ml],10,118959,DB00909,Zonisamide
,18372205,Cmax,Pharmacokinetic parameters obtained with a single administration of ZNS at 10mg/day were as follows: Cmax=13.1microg/ml; Tmax=4.0h; T(1/2)=33.0h; areas under the curves (AUCs)=720.3microg/mlh (values represent the medians).,Pharmacokinetics and toxicity of zonisamide in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372205/),[μg] / [ml],13.1,119361,DB00909,Zonisamide
,18372205,Tmax,Pharmacokinetic parameters obtained with a single administration of ZNS at 10mg/day were as follows: Cmax=13.1microg/ml; Tmax=4.0h; T(1/2)=33.0h; areas under the curves (AUCs)=720.3microg/mlh (values represent the medians).,Pharmacokinetics and toxicity of zonisamide in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372205/),h,4.0,119362,DB00909,Zonisamide
,18372205,T(1/2),Pharmacokinetic parameters obtained with a single administration of ZNS at 10mg/day were as follows: Cmax=13.1microg/ml; Tmax=4.0h; T(1/2)=33.0h; areas under the curves (AUCs)=720.3microg/mlh (values represent the medians).,Pharmacokinetics and toxicity of zonisamide in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372205/),h,33.0,119363,DB00909,Zonisamide
,18372205,areas under the curves (AUCs),Pharmacokinetic parameters obtained with a single administration of ZNS at 10mg/day were as follows: Cmax=13.1microg/ml; Tmax=4.0h; T(1/2)=33.0h; areas under the curves (AUCs)=720.3microg/mlh (values represent the medians).,Pharmacokinetics and toxicity of zonisamide in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18372205/),[μg] / [mlh],720.3,119364,DB00909,Zonisamide
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1139,127782,DB00909,Zonisamide
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1143,127783,DB00909,Zonisamide
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],133,127784,DB00909,Zonisamide
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],141,127785,DB00909,Zonisamide
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],140,127786,DB00909,Zonisamide
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],159,127787,DB00909,Zonisamide
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],21,127788,DB00909,Zonisamide
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],23,127789,DB00909,Zonisamide
,32048179,peak plasma cannabidiol concentrations,Median peak plasma cannabidiol concentrations was 13.1 ng/mL (interquartile range 6.8-39.3 ng mL); median time to peak of 2.0 h (interquartile range 2.0-4.0 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),[ng] / [ml],13.1,133353,DB00909,Zonisamide
,32048179,time to peak,Median peak plasma cannabidiol concentrations was 13.1 ng/mL (interquartile range 6.8-39.3 ng mL); median time to peak of 2.0 h (interquartile range 2.0-4.0 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),h,2.0,133354,DB00909,Zonisamide
,32048179,acute elimination half-life,Mean acute elimination half-life of oral cannabidiol was 6.2 h (standard deviation 1.8 h).,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),h,6.2,133355,DB00909,Zonisamide
,32048179,half-life of degradation,There was an observed half-life of degradation of 533 days noted for cannabidiol concentrations when stored for 0.6-3.1 years.,Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32048179/),d,533,133356,DB00909,Zonisamide
,15270757,clearance,"The reduction in plasma ZNS concentration after a 4.5-h hemodialysis was 52.0 +/- 7.6%, and the dialyzer (BLF-16GW) clearance of ZNS was 55.1 +/- 7.0 ml/min.",Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15270757/),[ml] / [min],55.1,136276,DB00909,Zonisamide
,6891599,peak plasma concentrations,"Mean peak plasma concentrations of AD-810 at 5.3-6.0 h after intake were 2.9, 5.1 and 13.0 micrograms/ml in Group A, B and C, respectively, and mean elimination half-life was about 60 h.","Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891599/),[μg] / [ml],2.9,144426,DB00909,Zonisamide
,6891599,peak plasma concentrations,"Mean peak plasma concentrations of AD-810 at 5.3-6.0 h after intake were 2.9, 5.1 and 13.0 micrograms/ml in Group A, B and C, respectively, and mean elimination half-life was about 60 h.","Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891599/),[μg] / [ml],5.1,144427,DB00909,Zonisamide
,6891599,peak plasma concentrations,"Mean peak plasma concentrations of AD-810 at 5.3-6.0 h after intake were 2.9, 5.1 and 13.0 micrograms/ml in Group A, B and C, respectively, and mean elimination half-life was about 60 h.","Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891599/),[μg] / [ml],13.0,144428,DB00909,Zonisamide
,6891599,elimination half-life,"Mean peak plasma concentrations of AD-810 at 5.3-6.0 h after intake were 2.9, 5.1 and 13.0 micrograms/ml in Group A, B and C, respectively, and mean elimination half-life was about 60 h.","Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891599/),h,60,144429,DB00909,Zonisamide
,9549648,terminal-phase half-life,"The terminal-phase half-life after the last dose was 63 to 69 hours, which is consistent with the half-life of 52 to 60 hours found in single-dose studies.","Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549648/),h,63 to 69,145190,DB00909,Zonisamide
,9549648,half-life,"The terminal-phase half-life after the last dose was 63 to 69 hours, which is consistent with the half-life of 52 to 60 hours found in single-dose studies.","Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549648/),h,52 to 60,145191,DB00909,Zonisamide
,9549648,Serum oral clearance,Serum oral clearance of 0.60 to 0.71 L/hr (0.121-0.132 mL/min/kg) was similar to that observed in other multiple-dose studies.,"Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549648/),[l] / [h],0.60 to 0.71,145192,DB00909,Zonisamide
,9549648,Serum oral clearance,Serum oral clearance of 0.60 to 0.71 L/hr (0.121-0.132 mL/min/kg) was similar to that observed in other multiple-dose studies.,"Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549648/),[ml] / [kg·min],0.121-0.132,145193,DB00909,Zonisamide
,6506134,Vm,"Vm and Km values of the Michaelis-Menten equation were calculated for 9 of the 10 patients by a new method: Vm averaged 1,272 (range 500-1,973) mg/day and Km averaged 25.1 (range 9.23-52.5) micrograms/ml.",Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506134/),[mg] / [d],"1,272",148325,DB00909,Zonisamide
,6506134,Km,"Vm and Km values of the Michaelis-Menten equation were calculated for 9 of the 10 patients by a new method: Vm averaged 1,272 (range 500-1,973) mg/day and Km averaged 25.1 (range 9.23-52.5) micrograms/ml.",Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6506134/),[μg] / [ml],25.1,148326,DB00909,Zonisamide
,11891100,transfer rates,The transfer rates were 92% via the placenta and 41-57% through the breast milk.,Pharmacokinetics of zonisamide in perinatal period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891100/),%,92,150178,DB00909,Zonisamide
,11891100,transfer rates,The transfer rates were 92% via the placenta and 41-57% through the breast milk.,Pharmacokinetics of zonisamide in perinatal period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891100/),%,41-57,150179,DB00909,Zonisamide
,11891100,elimination half-lives,"The first-order kinetics of zonisamide in the two infants was elimination half-lives of 109 and 61h, respectively.",Pharmacokinetics of zonisamide in perinatal period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891100/),h,109,150180,DB00909,Zonisamide
,11891100,elimination half-lives,"The first-order kinetics of zonisamide in the two infants was elimination half-lives of 109 and 61h, respectively.",Pharmacokinetics of zonisamide in perinatal period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11891100/),h,61,150181,DB00909,Zonisamide
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],13.38,152549,DB00909,Zonisamide
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],33.01,152550,DB00909,Zonisamide
,30238679,CMAX,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[μg] / [ml],34.13,152551,DB00909,Zonisamide
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],134.86,152552,DB00909,Zonisamide
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],352.95,152553,DB00909,Zonisamide
,30238679,AUC,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[h·μg] / [ml],452.76,152554,DB00909,Zonisamide
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.17,152555,DB00909,Zonisamide
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.08,152556,DB00909,Zonisamide
,30238679,CL/F,"The LP group had lower CMAX (13.38 μg/mL) compared to the L group (33.01 μg/mL) and LZ group (34.13 μg/mL), lower AUC (134.86 versus 352.95 and 452.76 hours·μg/mL, respectively), and higher CL/F (0.17 versus 0.08 and 0.07 L/kg/hr, respectively).","Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),[l] / [h·kg],0.07,152557,DB00909,Zonisamide
,30238679,half,The half-life that defined the terminal slope of the plasma concentration versus time curve (~5 hours) was similar to values previously reported for healthy dogs.,"Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30238679/),h,5,152558,DB00909,Zonisamide
,27901384,area under the concentration-time curve,The mean ± SD area under the concentration-time curve for the 30 mg/kg-in-water treatment (391.94 ± 237.00 h•μg/mL) was significantly greater than that for the 20 mg/kg-in-water (146.19 ± 66.27 h•μg/mL) and 20 mg/kg-in-PEG (87.09 ± 96.87 h•μg/mL) treatments.,Pharmacokinetics of zonisamide following rectal administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901384/),[h·μg] / [ml],391.94,167425,DB00909,Zonisamide
,27901384,area under the concentration-time curve,The mean ± SD area under the concentration-time curve for the 30 mg/kg-in-water treatment (391.94 ± 237.00 h•μg/mL) was significantly greater than that for the 20 mg/kg-in-water (146.19 ± 66.27 h•μg/mL) and 20 mg/kg-in-PEG (87.09 ± 96.87 h•μg/mL) treatments.,Pharmacokinetics of zonisamide following rectal administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901384/),[h·μg] / [ml],146.19,167426,DB00909,Zonisamide
,27901384,area under the concentration-time curve,The mean ± SD area under the concentration-time curve for the 30 mg/kg-in-water treatment (391.94 ± 237.00 h•μg/mL) was significantly greater than that for the 20 mg/kg-in-water (146.19 ± 66.27 h•μg/mL) and 20 mg/kg-in-PEG (87.09 ± 96.87 h•μg/mL) treatments.,Pharmacokinetics of zonisamide following rectal administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901384/),[h·μg] / [ml],87.09,167427,DB00909,Zonisamide
,30681361,maximum plasma concentration,"RESULTS Mean ± SD maximum plasma concentration of zonisamide for the single- and multiple-dose trials was 21.19 ± 3.42 μg/mL at 4.75 hours and 25.11 ± 1.81 μg/mL at 2.25 hours after administration, respectively.",Pharmacokinetics and safety of zonisamide after oral administration of single and multiple doses to Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681361/),[μg] / [ml],21.19,195490,DB00909,Zonisamide
,30681361,maximum plasma concentration,"RESULTS Mean ± SD maximum plasma concentration of zonisamide for the single- and multiple-dose trials was 21.19 ± 3.42 μg/mL at 4.75 hours and 25.11 ± 1.81 μg/mL at 2.25 hours after administration, respectively.",Pharmacokinetics and safety of zonisamide after oral administration of single and multiple doses to Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681361/),[μg] / [ml],25.11,195491,DB00909,Zonisamide
,30681361,plasma elimination half-life,"Mean plasma elimination half-life for the single- and multiple-dose trials was 13.34 ± 2.10 hours and 9.76 ± 0.93 hours, respectively.",Pharmacokinetics and safety of zonisamide after oral administration of single and multiple doses to Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681361/),h,13.34,195492,DB00909,Zonisamide
,30681361,plasma elimination half-life,"Mean plasma elimination half-life for the single- and multiple-dose trials was 13.34 ± 2.10 hours and 9.76 ± 0.93 hours, respectively.",Pharmacokinetics and safety of zonisamide after oral administration of single and multiple doses to Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681361/),h,9.76,195493,DB00909,Zonisamide
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],33,196011,DB00909,Zonisamide
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],46,196012,DB00909,Zonisamide
,28737428,LOD,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],4,196013,DB00909,Zonisamide
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],86,196014,DB00909,Zonisamide
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],93,196015,DB00909,Zonisamide
,28737428,LOQ,"Linear behavior was observed in the range of 0.1-3 μg/ml and 0.01-0.5 μg/ml for the AEDs and SUL, respectively, with LOD of 33, 46 and 4 ng/ml and LOQ of 86, 93 and 9 ng/ml for ZON, TOP and SUL, respectively.","Chromatographic determination of zonisamide, topiramate and sulpiride in plasma by a fluorescent 'turn-on' chemosensor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28737428/),[ng] / [ml],9,196016,DB00909,Zonisamide
,15795651,Cmin,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],2.8,210374,DB00909,Zonisamide
,15795651,Cmin,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],3.5,210375,DB00909,Zonisamide
,15795651,Cmax,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[μg] / [ml],5.1,210376,DB00909,Zonisamide
,15795651,AUC0-12,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[h·μg] / [ml],45.5,210377,DB00909,Zonisamide
,15795651,AUC0-12,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[h·μg] / [ml],50.3,210378,DB00909,Zonisamide
,15795651,CL/F,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[ml] / [h],2778.5,210379,DB00909,Zonisamide
,15795651,CL/F,"Steady-state dosing of ZNS did not significantly affect the mean Cmin (mean +/- SD: 2.8 +/- 1.4 vs 3.5 +/- 2.4 microg/mL), Cmax (5.1 +/- 3.0 vs 5.1 +/- 3.0 microg/mL), AUC0-12 (45.5 +/- 22.6 vs 50.3 +/- 32.1 microg.h/mL), and CL/F (2778.5 +/- 1368.5 vs 3052.1 +/- 2744.9 mL/h) of LTG measured before (day -1) and after (day 35) ZNS administration, respectively.",Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795651/),[ml] / [h],3052.1,210380,DB00909,Zonisamide
,9004190,total clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],15.4,210759,DB00909,Zonisamide
,9004190,total clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],12.7,210760,DB00909,Zonisamide
,9004190,renal clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],5.4,210761,DB00909,Zonisamide
,9004190,renal clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],3.3,210762,DB00909,Zonisamide
,9004190,non-renal clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],7.7,210763,DB00909,Zonisamide
,9004190,non-renal clearance,"The area under the curve of the free and the erythrocyte concentration did not differ between the two study phases whereas the area under the curve of the total serum concentration was significantly lower on the day of the operation, and this was associated with significant increases in total clearance (15.4 compared with 12.7 mL kg-1 h-1, P < 0.05, n = 9) and renal clearance (5.4 compared with 3.3 mL kg-1 h-1, P < 0.05, n = 3), and non-significant change in non-renal clearance (7.7 on the day of operation compared with 8.4 mL kg-1 h-1 on the post-operation day, n = 3).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[ml] / [h·kg],8.4,210764,DB00909,Zonisamide
,9004190,volume of distribution,"Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 L kg-1, P < 0.05, n = 9).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[l] / [kg],1.48,210765,DB00909,Zonisamide
,9004190,volume of distribution,"Zonisamide distribution was also altered by the operative procedure, as evidenced by a higher volume of distribution (1.48 compared with 0.87 L kg-1, P < 0.05, n = 9).",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[l] / [kg],0.87,210766,DB00909,Zonisamide
,9004190,maximum binding capacity,"The maximum binding capacity to erythrocytes (31.6 vs 29.7 micrograms mL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28%) and the proportionality constant (+24%) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation.",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[μg] / [ml],31.6,210767,DB00909,Zonisamide
,9004190,maximum binding capacity,"The maximum binding capacity to erythrocytes (31.6 vs 29.7 micrograms mL-1) did not differ on the two days; however, increases in the dissociation binding constant (+28%) and the proportionality constant (+24%) were observed on the day of the operation, suggesting that the zonisamide concentration in erythrocytes was greater on the day of the operation.",Pharmacokinetic study of zonisamide in patients undergoing brain surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004190/),[μg] / [ml],29.7,210768,DB00909,Zonisamide
,15871637,maximum observed plasma concentration (C(max)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[μg] / [ml],70.8,230246,DB00909,Zonisamide
,15871637,maximum observed plasma concentration (C(max)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[μg] / [ml],69.2,230247,DB00909,Zonisamide
,15871637,area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[h·μg] / [ml],689.3,230248,DB00909,Zonisamide
,15871637,area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[h·μg] / [ml],661.8,230249,DB00909,Zonisamide
,15871637,oral clearance,"In the presence of valproic acid, mean zonisamide oral clearance (1.23 L/h) and elimination half-life (52.5 hours) are generally consistent with values reported for healthy volunteers receiving zonisamide monotherapy.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[l] / [h],1.23,230250,DB00909,Zonisamide
,15871637,elimination half-life,"In the presence of valproic acid, mean zonisamide oral clearance (1.23 L/h) and elimination half-life (52.5 hours) are generally consistent with values reported for healthy volunteers receiving zonisamide monotherapy.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),h,52.5,230251,DB00909,Zonisamide
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00909,Zonisamide
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00909,Zonisamide
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00909,Zonisamide
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00909,Zonisamide
,23106522,half-life,"Zonisamide displays predictable, dose-dependent pharmacokinetics and has a half-life of ~60 h, allowing once- or twice-daily administration.","Zonisamide: its pharmacology, efficacy and safety in clinical trials. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106522/),h,60,236397,DB00909,Zonisamide
,9300137,bioavailability,"However, the bioavailability of the three preparations was approximately 100%.",Utility of a rectal suppository containing the antiepileptic drug zonisamide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300137/),%,100,250683,DB00909,Zonisamide
,15511691,half-life,"It is rapidly and completely absorbed and has a long half-life (63-69h in healthy volunteers) which allows twice-daily, or even once-daily, dosing.","Zonisamide: chemistry, mechanism of action, and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15511691/),h,63-69,250903,DB00909,Zonisamide
,32215749,absolute bioavailability,"Intranasal route revealed a low absolute bioavailability (54.95%) but the highest value of the ratio between the area under the curve (AUC) between brain and plasma, suggesting lower systemic adverse events and non-inferior effects in central nervous system comparatively to intravenous and oral routes.",Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215749/),%,54.95,251840,DB00909,Zonisamide
,27007995,clearance (CL),"In the final model, the estimated value of clearance (CL) was 23.25 L/h, the volume of distribution of the central compartment (Vc) was 34.50 L, the intercompartmental clearance (Q) was 20.22 L/h, and the Ka was 0.026 h(-1).",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),[l] / [h],23.25,252248,DB00909,Zonisamide
,27007995,volume of distribution of the central compartment (Vc),"In the final model, the estimated value of clearance (CL) was 23.25 L/h, the volume of distribution of the central compartment (Vc) was 34.50 L, the intercompartmental clearance (Q) was 20.22 L/h, and the Ka was 0.026 h(-1).",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),l,34.50,252249,DB00909,Zonisamide
,27007995,intercompartmental clearance (Q),"In the final model, the estimated value of clearance (CL) was 23.25 L/h, the volume of distribution of the central compartment (Vc) was 34.50 L, the intercompartmental clearance (Q) was 20.22 L/h, and the Ka was 0.026 h(-1).",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),[l] / [h],20.22,252250,DB00909,Zonisamide
,27007995,Ka,"In the final model, the estimated value of clearance (CL) was 23.25 L/h, the volume of distribution of the central compartment (Vc) was 34.50 L, the intercompartmental clearance (Q) was 20.22 L/h, and the Ka was 0.026 h(-1).",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),1/[h],0.026,252251,DB00909,Zonisamide
,27007995,peripheral volume of distribution (Vp),"The peripheral volume of distribution (Vp) was 1,429 L for single dose and 1,003 L for multiple doses.",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),l,"1,429",252252,DB00909,Zonisamide
,27007995,peripheral volume of distribution (Vp),"The peripheral volume of distribution (Vp) was 1,429 L for single dose and 1,003 L for multiple doses.",Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27007995/),l,"1,003",252253,DB00909,Zonisamide
,15519127,Ki,"The estimated Ki for zonisamide inhibition of CYP3A4 was 1076 microM, 12 times higher than typical unbound therapeutic serum zonisamide concentrations.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),μM,1076,260946,DB00909,Zonisamide
,15519127,t1/2,"The observed mean zonisamide t1/2 (36.3h), relative to approximately 65 h reported in subjects on zonisamide monotherapy, reflects known CYP3A4 induction by carbamazepine.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),h,36.3,260947,DB00909,Zonisamide
,15519127,t1/2,"The observed mean zonisamide t1/2 (36.3h), relative to approximately 65 h reported in subjects on zonisamide monotherapy, reflects known CYP3A4 induction by carbamazepine.",Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519127/),h,65,260948,DB00909,Zonisamide
,19360758,flow rate,"The baseline separation of all the peaks was achieved with 0.1% triethylamine (pH 6.0):acetonitrile (72:28, v/v) at a flow rate of 1 mL/min on a Zorbax C(8) column.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),[ml] / [min],1,262031,DB00909,Zonisamide
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,11.0,262032,DB00909,Zonisamide
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,2.42,262033,DB00909,Zonisamide
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,5.02,262034,DB00909,Zonisamide
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,36.4,269758,DB00909,Zonisamide
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,54.2,269759,DB00909,Zonisamide
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,27.1,269760,DB00909,Zonisamide
,3750373,t1/2,"The approximate values for t1/2 were 36.4 h in plasma and 54.2 h in RBC for patients treated with CBZ, and 27.1 h in plasma and 35.8 h in RBC for patients treated with PHT.",Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750373/),h,35.8,269761,DB00909,Zonisamide
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00909,Zonisamide
